This program is supported by an independent education grant from Lilly. This education program has been designed for healthcare professionals globally, excluding the UK.

This is a Clinical Update session as part of the ASNR Annual Meeting programme. Participation is available exclusively to registered attendees; please ensure your conference registration is active.

Join leading Alzheimer’s disease experts Dr. Tammie L. S. Benzinger, Dr. Petrice M. Cogswell and Dr. Ana M. Franceschi, for this accredited in-person session. Using real-world clinical vignettes and AI-enhanced imaging simulations, this masterclass explores the latest evidence-based protocols for identifying, mitigating, and managing ARIA.

Participants will gain practical insights into patient-centered risk stratification, multidisciplinary escalation pathways, and the evolving radiologic nuances essential for the safe implementation of anti-amyloid therapies in clinical practice.

Credits: AMA PRA Category 1 Credits™ (00.75.00 hours)

Session Highlights

This session uses real-world clinical vignettes to examine the newest evidence guiding ARIA detection, management, and coordinated response across multidisciplinary teams.

• Examine the latest evidence-based guiding patient-centered ARIA risk discussions. Through rapid referral cases, faculty compare approaches to integrating emerging evidence-based diagnostic pathways, patient-centered goals, and eligibility considerations within contemporary shared decision-making.
• Review subtle early ARIA presentations with updated radiologic and clinical insights. Explore AI-enhanced imaging simulations and serial MRI studies, with faculty discussing inter-reader variability, current interpretation nuances, and how evolving evidence informs precise grading thresholds.
• Explore current strategies for ARIA risk mitigation across diverse clinical scenarios. Using real-time simulations, faculty discuss evidence-informed approaches to dose adjustment, risk-stratification, and monitoring intervals as reflected in the newest guidance and clinical trial data.
• Discuss multidisciplinary ARIA escalation pathways shaped by emerging data. Walk through high-stakes "STAT" MRI scenarios from the Emergency Department to radiology and neurology coordination, highlighting structured reporting language, closed-loop communication practices, and system-level readiness benchmarks

Who Should Attend?

This program is designed for healthcare professionals involved in Alzheimer’s disease diagnosis, imaging, treatment, and acute evaluation, including:

• Neuroradiologists and Radiologists (MD/DO)
• Neurologists specializing in cognitive disorders
• Dementia Specialists (MD/DO/NP/PA)
• Geriatricians
• Emergency Medicine Physicians and acute evaluation teams
• Nurse Practitioners and Physician Assistants
• MDT Healthcare Professionals involved in ARIA monitoring
• Neuroradiology and Radiology Fellows and Trainees

Faculty

Tammie L. S. Benzinger, MD, PhD, is the Hugh Monroe Wilson Professor of Radiology and Chief of MRI Service at the Mallinckrodt Institute of Radiology at Washington University School of Medicine. Her work focuses on PET and MRI biomarkers for Alzheimer’s disease and related neurodegenerative disorders, and she directs imaging programs for the Knight Alzheimer’s Disease Research Center, DIAN, and DIAN-TU. A recognized leader in neuroradiology, she has received multiple national awards and is known for advancing early detection of degenerative brain disease through innovative imaging science.

Petrice M. Cogswell, MD, PhD, is an Associate Professor of Radiology and Consultant in the Division of Neuroradiology at Mayo Clinic, Rochester. A leading expert in advanced neuroimaging, her research focuses on the intersection of quantitative MRI, machine learning, and biomarker modeling to enhance the diagnosis of neurodegenerative disorders. Dr. Cogswell is a prominent figure in the field of Alzheimer’s disease, currently serving as Vice Chair of the ARIA and Dementia Study Group for the American Society of Neuroradiology and as a member of the AHA Amyloid-Related Imaging Abnormalities Summit Planning Committee. Her work is instrumental in developing the imaging protocols and clinical workflows used to detect and monitor ARIA in patients receiving anti-amyloid immunotherapies. Dr. Cogswell also serves as a Co-Investigator for several NIH-funded initiatives, including the Alzheimer’s Clinical Trials Consortium (ACTC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), dedicated to advancing safe, personalized care through innovative imaging science.

Ana M. Franceschi, MD, PhD is an Associate Professor of Radiology at the Zucker School of Medicine at Hofstra/Northwell and a leading neuroradiologist at Northwell Health. Her work specializes in neurological molecular imaging, with a distinguished focus on the advancement of brain PET/MRI and hybrid imaging techniques to combat dementia and neurodegenerative disease. A prolific researcher, she was awarded the Foundation of the ASNR Boerger Research Fund for Alzheimer’s Disease and Neurocognitive Disorders to study abnormal tau accumulation in Primary Progressive Aphasia (PPA) and currently serves as Principal Investigator on studies seeking universal biomarkers for the A/T/N classification of dementia.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from Lilly.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Tammie Benzinger, MD, PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Research Support / Grants: NIH/NIA, Alzheimer’s Association, GHR Foundation, Anonymous Foundation, Dominantly Inherited Alzheimer Network (DIAN) Trials Unit (TU) Pharma Consortium, Hope Center for Neurological Disorders, Barnes-Jewish Hospital Foundation, NIH-AMP, American Society for Neuroradiology, Eli Lily/Avid Radiopharmaceuticals, LMI/Lantheus, Siemens, Hyperfine; Clinical Trials (Investigator): Eli Lilly, Roche, Biogen, J&J, Eisai; Consulting/Advisory Board: Biogen, Eisai, Lilly, Bristol Myers, J&J, Merck, Siemens; Travel: J&J, Eisai. Dr. Benzinger intends to discuss non-FDA uses of drug products and/or devices only in relation to products for which she has no financial relationships. She will disclose to the audience when this discussion takes place.

Petrice M. Cogswell, MD, PhD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Honoraria: Eisai. Dr Cogswell participates in the Data and Safety Monitoring Board for Eisai and Lilly (with no financial compensation). Dr Cogswell does not intend to reference unlabeled or unapproved uses of drugs or products.

Ana M. Franceschi, MD, PhD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board: Biogen, Eli Lilly, Roche/Genentech, Icometrix, Cortechs ai; Consultant: Biogen, Eisai, Eli Lilly, Roche/Genentech, Siemens Healthineers, Life Molecular Imaging/Lantheus, Blue Earth Diagnostics, MIM Software, Icometrix, Cortechs ai, PeerView, Medical Learning Institute, Springer Nature, Medscape, Med Learning Group. Dr Franceschi does not intend to reference unlabeled or unapproved uses of drugs or products.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no additional cost to participate in this program; however, this session is part of the ASNR Annual Meeting programme. Participation is open exclusively to registered attendees; please ensure your conference registration is active.

This continuing education activity is active starting May 18th 2026, and will expire on May 18th 2026.

Estimated time to complete this activity: 45 minutes.